Skip to content

American Society of Hematology Annual Meeting 2022

The Mass General Cancer Center will present their latest research at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, LA. In its 64th year, the ASH Annual Meeting & Exposition offers educational meetings and workshops for hematology professionals from around the world.

The 64th annual 2022 American Society of Hematology (ASH) Annual Meeting takes place in-person in New Orleans, LA, and virtually. The ASH Annual Meeting & Exposition offers educational meetings and workshops for hematology professionals from around the world.

The Mass General Cancer Center will have a strong presence at this year's event, with dozens of leaders scheduled to present their latest hematologic research and lead educational sessions. 

Friday, December 9, 2022


Annemarie E. Fogerty, MD

1:30 pm: River City Ballroom (Mardi Gras World)
Session: Blood Buddies: Adult Clinical Classical Hematology (In-Person)

Saturday, December 10, 2022


Hanny Al-Samkari, MD

8:00 am: Camp (Hilton New Orleans Riverside)
Session: ITP/TTP—and Other Scary Causes of Thrombocytopenia

David Kuter, MD, DPhil

9:30 am: 291-292
Warm AIHA and the Best Treatment Strategies

Jacob Soumerai, MD

9:30 am: La Nouvelle Orleans Ballroom C
Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination With the BTK Inhibitor Zanubrutinib in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Noopur S. Raje, MD

12:00 pm: R02-R05
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients With Relapsed or Refractory Multiple Myeloma

Mark B. Leick, MD

2:00 pm: La Nouvelle Orleans Ballroom AB
Patients With Deleterious Germline Variants in STXBP2 Develop Toxicity After CAR-T Cell Therapy With Axicabtagene Ciloleucel

Hanny Al-Samkari, MD

4:00 pm: 243-245
Chemotherapy-Induced Thrombocytopenia

Jeremy S. Abramson, MD

5:30 pm: Hall D
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) With Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Philip Amrein, MD

5:30 pm: Hall D
Phase I Study of Ixazomib With Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Amir Fathi, MD

5:30 pm: Hall D
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia

Patrick Johnson, MD

5:30 pm: Hall D
Longitudinal Patient-reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

David Kuter, MD, DPhil

5:30 pm: Hall D
Phase 3, Randomized, Double-blind, Placebo-controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Rachel Rosovsky, MD, MPH

5:30 pm: Hall D
Patients Reporting of Breathlessness After Experiencing Venous Thromboembolic Event

Sunday, December 11, 2022


Anna Marneth, PhD

9:30 am: 275-277
Mutant Srsf2 Diminishes Jak2V617F-Induced Erythrocytosis in Mice and Is Associated With Lower Hemoglobin in Patients With Chronic Phase JAK2-Mutant MPN

Zachariah DeFilipp, MD

12:00 pm: 208-210
Spatial Transcriptomics of Tissue-based Immune Response to Acute Graft-Versus-Host Disease of the Lower Gastrointestinal Tract

Jeremy S. Abramson, MD

4:30 pm: Hall E
Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) With Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) as Second-Line (2L) Treatment in Patients With Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Hanny Al-Samkari, MD

4:30 pm: 288-290
A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia

Matthew J. Frigault, MD

6:00 pm: Hall D
Phase 1 Study of CART-Ddbcma for the Treatment of Subjects With Relapsed and /or Refractory Multiple Myeloma

Joan How, MD

6:00 pm: Hall D
Immunologic Responses to SARS-CoV-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations With Infections

David Kuter, MD, DPhil

6:00 pm: Hall D
Clinical Predictors of Response to Rilzabrutinib Therapy in Patients With Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

David J. Lee, MD, MPH, MMSc

6:00 pm: Hall D
Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa

Orly Leiva, MD

6:00 pm: Hall D
Trends in All-cause and Cardiovascular Mortality Among Patients With Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

Elizabeth O'Donnell, MD

6:00 pm: Hall D
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Monday, December 12, 2022


Yi-Bin Chen, MD

10:30 am: 252-254
RGI-2001 Infusion for Prevention of Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation

Michael Mazzola, BS

2:45 pm: 252-254
Cap-Independent Protein Translation in Hematopoiesis

Bimarzhan Assatova

4:30 pm: 391-392
KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients With Mature T and NK/T-Cell Lymphomas

Rebecca S. Karp Leaf, MD

4:30 pm: 388-390
Clinical Experience With Afamelanotide for the Protoporphyrias in the United States

David Kuter, MD, DPhil

4:30 pm: Great Hall AD
Moving Forward in Hemolytic Anemias: Acquired and Hereditary—Clinical Discussant for Cold Agglutinin Disease

Hanny Al-Samkari, MD

6:00 pm: Hall D
Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients With Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response

Leora S. Boussi, MD

6:00 pm: Hall D
Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients With Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Andrew Branagan, MD, PhD

6:00 pm: Hall D
Clinical Effectiveness and Long-term Serologic Responses of COVID-19 Vaccination in Patients With Multiple Myeloma and Waldenström Macroglobulinemia

Tejaswini Dhawale, MD

6:00 pm: Hall D
Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Mihir Gupta, MD

6:00 pm: Hall D
A Rapid Genotyping Assay for CSF Accelerates Diagnosis and Treatment Initiation for CNS Malignancies

Orly Leiva, MD

6:00 pm: Hall D
Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients With Myeloproliferative Neoplasms Admitted for Myocardial Infarction

Daniel Pearson, MD

6:00 pm: Hall D
Use of Clinical Decision Support to Improve the Laboratory Evaluation of Monoclonal Gammopathies

Jacob Soumerai, MD

6:00 pm: Hall D
A Phase 1 Study With the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination With Zanubrutinib (ZANU) in Patients (Pts) With Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data